RPRekha Pai

Rekha Pai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rekha Pai has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of KRAS Mutations in EGFR, ALK, and ROS1-negative Nonsmall-cell Lung Cancer: A Single-center Study

    by Sharmila Annadurai, A. Prisca Santhanam, Sathyakumar Rima, Rajadurai Abarna, Thomas Alex Kodiatte, Ashish Singh, Anjana Joel, Raju Titus Chacko, Rekha Pai

    Background: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major contributor to cancer-related mortality globally. The Kirsten rat sarcoma viral oncogene homolog ( KRAS ) oncogene is among the most frequently mutated genes in NSCLC, with significant implications for targeted therapy, including KRAS G12C inhibitors. However, data on KRAS mutation prevalence among Indian patients remain limited. Materials and Methods: In this retrospective study, we analyzed 93 biopsy-confirmed NSCLC cases from January 2020 to December 2021 that were negative for epidermal growth factor receptor ( EGFR ), anaplastic lymphoma kinase ( ALK ), and c-ros oncogene 1 ( ROS1 ) alterations. KRAS mutation testing was performed using Sanger sequencing. To support rapid mutation detection, we also designed an in-house drop-off droplet digital polymerase chain reaction (ddPCR) assay targeting codons 12, 13, and 61, and validated it in a randomly selected subset of 30 cases. Results: Sanger sequencing identified KRAS mutations in 26 of 93 cases (28%), predominantly in exon 2 (25%) and to a lesser extent in exon 3 (3%). While G12C (57%), G12D (30%), and G12V (9%) were the most frequently observed variants, the Q61H variant was the only variant in exon 3. The drop-off ddPCR assay showed 100% sensitivity, specificity, and concordance with Sanger sequencing. Conclusion: These findings highlight a substantial burden of KRAS mutations, particularly the G12C variant, among EGFR, ALK , and ROS1 -negative NSCLC cases in the Indian population. This study also demonstrates the reliability and clinical utility of a cost-effective, in-house ddPCR assay for KRAS mutation screening.

  • Open Access

    A Prospective Study on Challenges in the Management of Indeterminate Thyroid Nodules Without Molecular Testing

    by Jeyashanth Riju, Nihal Thomas, V. Thomas Paul, Deepak Thomas Abraham, M. Paul Jacob, J. Anne Prabhu, Marie Therese, Remya Rajan, J. Anish Cherian, Shawn Thomas, et al.

    Introduction: Treating indeterminate thyroid nodules (ITNs) without validated molecular testing (MT) has been challenging. However, adding specific clinical and radiological parameters helps us to decide on treatment for a few individuals. The risk of malignancy in ITN after eliminating the obvious risk parameters needs to be studied. Methods: This prospective single‐centre analysis included patients who underwent fine needle aspiration cytology (FNAC) of thyroid between March 2022 and October 2023. The study included patients with thyroid nodules classified as Bethesda III/IV who subsequently underwent surgery. Different clinicopathological and FNAC‐related parameters were statistically analysed to predict malignancy, after excluding those factors that would strongly suggest malignancy. Results: Among 1501 patients who underwent FNAC, 207 met the inclusion criteria. The mean age of the study population was 39 ± 12.1 years, and the majority were women (80.2%). Among the ITNs, 86% were Bethesda III, and 14% were Bethesda IV nodules. The risk of malignancy in Bethesda III and IV nodules was 67.4% and 69%, respectively. On multivariate analysis, it was noted that hypothyroidism was the single independent factor that predicted malignancy associated with a significant odds of 0.309 (95%CI:0.127–0.784, p = 0.013). The most common malignancy among ITNs was the follicular variant of papillary thyroid carcinoma. Conclusion: Women less than 40 years of age, in this cohort, had a higher risk of malignancy compared to the Western population. More than half of the patients diagnosed with ITN underwent surgery. Hypothyroidism is an independent factor that may predict the risk of malignancy in ITNs, and this needs external validation. Rule‐in MT might be important in categorizing patients with ITN in the Indian population.

  • Open Access

    Real World Outcomes with Tepotinib in a Series of Indian Patients with MET Exon 14 Skipping positive Non-Small Cell Lung Cancer

    by Rohini Sebastian, Josh Thomas Georgy, Arun George, Prisca Santhanam, Raiza Philip, Anjana Joel, Ajoy Oommen John, Deepa Susan Joy Philip, Divya Bala Thumaty, Thomas Alex Kodiatte, et al.

    Real world outcomes with Tepotinib in a series of Indian patients with MET exon 14 skipping positive non-small cell lung cancer Rohini Sebastian1*, Josh Thomas


  • Dopamine receptor expression predicts cabergoline response in persistent somatotroph adenoma

    by Remya Rajan R., Hesarghatta Shyamasunder, Geeta Chacko, Dhananjayan S, Ranjani Jeyachandran, Ari G. Chacko, Krishna Prabu, Simon Rajaratnam, Nitin Kapoor, Nihal Thomas, et al.

    In a resource limited setting, cabergoline remains an important part of medical management in acromegaly patients with persistent disease after surgery. Response to medical treatment may depend on the receptor expression in these tumors. To study the dopamine receptor subtype2 (D2R) and somatostatin receptor subtypes2&5(SSTR2&SSTR5) expression in somatotropinomas by immunohistochemistry (IHC) and real time/quantitative polymerase chain reaction(qPCR). Also, to determine the relation between density of D2R expression and remission with cabergoline therapy. This study included 30 patients with somatotropinomas who underwent surgery and had persistent disease post-surgery treated with cabergoline. Immunostaining and qPCR for D2R, SSTR2&5 were performed on archived GH secreting pituitary adenoma specimens. The clinical, biochemical and radiological details were collected from the hospital electronic medical records. D2R was the predominantly expressed receptor followed by SSTR2 and SSTR5. The median(range) duration of cabergoline therapy was 20(6-72) months. 23% (7/30) of patients achieved normalization of IGF-I or GH < 1ng/ml (random/post glucose suppression) with cabergoline. Subjects with baseline IGF-1 < 1.5 times the upper limit of normal were more likely to achieve remission with cabergoline. D2R mRNA expression was significantly higher in patients in remission. On ROC curve analysis, a D2R ΔΔ CT of 19.2 (19-fold higher expression compared to normal tissue) predicted remission with cabergoline with a sensitivity of 71% and specificity of 74% (AUC 0.745). D2 receptor profiling of growth hormone secreting pituitary tumors and post-operative IGF-1 level at 3 months are helpful to predict response to medical treatment with cabergoline.


  • The Impact of Ultrasound-Guided Fine-Needle Aspiration Cytology in the Management of Thyroid Nodule

    by Jeyashanth Riju, Nihal Thomas, Thomas V. Paul, Deepak Abraham, Paul Mazhuvanchary Jacob, Anne Jennifer Prabhu, Marie Therese M, Remya Rajan, Anish Jacob Cherian, Shawn Thomas, et al.

    Fine-needle aspiration cytology (FNAC) is the gold standard for evaluating thyroid nodules, which groups thyroid nodules into six categories based on The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). Further management will depend upon the category. Ultrasound-guided fine needle aspiration cytology (USG-FNAC) has revolutionized the sample yield in FNAC. The palpatory method is being used in many developing countries due to the non-availability of suitable ultrasound resources and trained radiologists or surgeons. This paper intends to compare both methods of FNACs with respect to sample yield. This was a 456-patient mixed cohort analysis that included prospectively collected data from 256 patients with USG-FNAC, over 1 year, compared with a historical control of 200 patients who had palpation-guided FNAC(P-FNAC). The influence of the method of FNAC on TBSRTC classification and changes in the surgical intervention were studied. Univariate and multivariate analyses were performed to predict the factors that influenced the adequacy of FNAC. The mean age of the study population was 42.6 ± 12.7 years and 75% were women. FNAC was inadequate in 17.5% of the USG-FNAC group and 24.6% of P-FNAC, after excluding cystic nodules. Performing USG-FNAC increased the adequacy of FNA by 7.2% (p = 0.046) and increased the chance of detecting benign nodules by 17.3% (p < 0.001) compared to the palpation method. There was a reduction in the number of surgeries performed in the USG-FNAC group by 10.9% (p = 0.01). On multivariate analysis, USG-FNAC was associated with decreased sample inadequacy (OR 0.23; 95% CI 0.09–0.59; p < 0.002), presence of cystic component (OR 11.20; 95% CI 1.74–72.04; p = 0.011), or solid-cystic component in the tumor in USG (OR 2.82; 95% CI 1.04–7.62; p = 0.041) and had a negative impact on adequacy of the FNAC sample. USG-FNAC–guided procedures not only helped in improving sample adequacy, but also improved benign categorisation of thyroid nodules. It eventually reduced the number of unnecessary surgical procedures performed. Consistency of the nodule had a significant impact on FNAC adequacy.


  • Comparative analysis of mutational patterns in triple negative breast cancer before and after neoadjuvant chemotherapy in patients with residual disease

    by Ashish Singh, Josh Thomas Georgy, Sakthi Dhananjayan, Elanthenral Sigamani, Ajoy Oommen John, Anjana Joel, Jagan Chandramohan, Rajadurai Abarna, Grace Rebekah, Selvamani Backianathan, et al.


  • Droplet digital PCR (ddPCR) using FFPE DNA to assess methylation status of MGMT gene among patients with IDH mutant astrocytoma and IDH wild-type glioblastoma

    by Rajadurai Abarna, Ranjani J, Geeta Chacko, Rekha Pai

    MGMT promoter methylation analysis in formalin-fixed paraffin-embedded (FFPE) tissues can be challenging since the DNA obtained is often fragmented. Bisulfite conversion, which is essential to determine methylation status, further degrades DNA. While conventional methylation-specific PCR (MSP) and pyrosequencing assays have long been used to determine the methylation status of MGMT , this study was designed to determine the utility of one-tube DNA extraction method coupled with a droplet digital PCR (ddPCR) assay, to study the epigenetic changes in the promoter region of the MGMT gene using DNA obtained from FFPE. The FFPE blocks of 30 (n=30) patients with Central Nervous System (CNS) WHO grade 4 tumours, previously tested by MSP (2011–2021) were retrieved; DNA was extracted using one-tube extraction method and bisulfite converted. All converted samples were analyzed for methylation status of the MGMT promoter region with a laboratory designed Methylation-Specific ddPCR (MS ddPCR) using degenerate primers and probes that were labelled with FAM or HEX flurocein dye. Of the 30 cases, 20 cases were MGMT methylated and 10 cases were unmethylated by MS ddPCR. The results of MS ddPCR were then compared with those obtained by MSP and found to be concordant in 93.3% (28/30) of the cases and discordant in 2 cases. The Cohen’s kappa coefficient (κ) was 0.84. The sensitivity, specificity, positive predictive value and negative predictive value of the assay in detecting the methylation status was found to be 95%, 90%, 95% and 90%. The results show that MS ddPCR is a valuable tool to detect the methylation status of MGMT in FFPE with high sensitivity. This method is cost-effective and easy to perform and could be an attractive alternative to the routine method of MSP.


  • Open Access

    Subclonal evolution in the mutational landscape of early Triple negative breast cancer (TNBC) on multi-agent chemotherapy: Comparison of Pre- And Post-Neoadjuvant Chemotherapy (NAC) Samples Of TNBC Patients With Residual Disease

    by Ashish Singh, Josh Thomas Georgy, Sakthi Dhananjayan, Elanthendral Sigamani, Ajoy Oommen John, Anjana Joel, Jagan Chandramohan, Rajadurai Abarna, Grace Rebekah, Selvamani Backianathan, et al.

    Background Triple-negative breast cancer (TNBC) with residual disease post chemotherapy, have increased chance of relapse and lower survival with varying degree of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). However, the risk of recurrence is high among those who do not achieve pCR and characterizing the mutational landscape of this fairly heterogeneous subset of patients might provide some valuable insights. Methods The archival paired (pre- and post-NAC) samples of 25 patients with histopathologically confirmed TNBC with residual disease who received anthracycline-taxane as NAC, were processed by next-generation sequencing using a 72-gene panel. Somatic mutations were identified using UMI corrected .clc pipeline; gene annotation of the variants performed using VeP program. Data was analysed using IBM SPSS Statistics v23 and R v4.1.2 (RStudio 2021.09.1). The K-means algorithm was used to classify the samples into k number of clusters. Results Among all 50 tumour samples, a median of 12 mutations (IQR 7-17.25) per sample was observed. Missense mutations accounted for the overwhelming majority (73.5%). The predominant mutations in the pre-NAC samples were TP53(80%), PMS2(64%), PTEN(64%), ERBB2(48%), NOTCH1(44%) while the mutational profile was slightly different among the post-NAC samples: TP53(84%), AR(60%), PTEN(60%), PMS2(44%), ERBB2(40%). The burden of mutations did not differ among patients who received platinum or not (12.8 ± 6.9 Vs 11.25 ± 4.9; p-value 0.94), though there were several private mutations in the former group. Similarly, the tumor mutation burden was not very different among those with (n = 5) and without recurrence (14 ± 7.2 Vs 12.2 ± 6.6; p-value 0.49). The K-means clustering demonstrated two clusters -all patients with recurrence, except one, in the larger cluster. Conclusions The burden of mutations among the pre- and post-NAC samples mostly remained the same, although, mutations in specific genes for example- increase in mutations in the AR gene post-NAC, was noted. TP53 mutations predominated pre- and post-NAC. There was no significant difference in mutational burden and there were no recurrent / co-occurring mutations among those who received platinum therapy after NAC or among those with recurrence. The data throws significant light on the somatic mutational load, spectrum and heterogeneity, among TNBCs with residual disease.

  • Impact of Grade on Survival in Pleomorphic Xanthoastrocytoma and Low Prevalence of BRAF V600E Mutation

    by Edmond Jonathan Gandham, Abhijit Goyal-Honavar, Daniel Beno, Rekha Pai, Rajesh Balakrishan, Anita Jasper, Mahasampath Gowri, Ranjith K. Moorthy, Ari George Chacko, Geeta Chacko


  • ZFTA (Zinc Finger Translocation Associated) Fusion in Supratentorial Ependymomas: Low Prevalence in South Asians and No Correlation with Survival

    by Abhijit Goyal-Honavar, Ambritha Balasundaram, Immanuel Paul Thayakaran, Malavika Babu, Rekha Pai, Julie Joseph, Ranjani Jayachandran, Ari G. Chacko, Leni G. Mathew, Rajesh Balakrishnan, et al.